A Phase 1 interventional study of MTX-463 and Placebo in Healthy, sponsored by Mediar Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-17.
Sponsored by Mediar Therapeutics · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.
SAD Portion
The SAD portion of the study will consist of 4 planned dosing cohorts each comprising 8 healthy participants. The starting dose will be 4 mg/kg (Cohort 1) with subsequent planned doses of 8 mg/kg (Cohort 2), 16 mg/kg (Cohort 3), and 30 mg/kg (Cohort 4). Planned doses may be adjusted in response to the data. Additional participants and/or additional dosing cohorts may be added as needed based on the data.
Within each cohort, participants will be randomly assigned to receive MTX-463 or matched placebo. The first 2 participants (sentinel participants) within each cohort will be randomized 1:1 to receive MTX-463 or placebo on Day 1. These participants will be monitored for 24 hours, and after review of the safety data from both participants and approval by the study Investigator and Sponsor's responsible medical officer (SRMO), the additional 6 participants will be randomized to study drug (n=5 MTX-463; n=1 placebo).
Each participant will undergo assessments at specified timepoints on Days 1 through 60. End-of-Study (EOS) procedures will be completed on Day 28 or upon early termination (ET). An End-of-Follow-up (EOF) assessment of PK and ADA will be completed on Day 60.
MAD Portion
The MAD portion of the study will consist of 3 planned dosing cohorts. Each cohort will comprise 8 healthy participants (n=6 MTX-463; n=2 placebo). The starting dose will be a 6.6 mg/kg loading dose and 4 mg/kg maintenance doses (Cohort 1) with subsequent planned doses of a 13 mg/kg loading dose and 8 mg/kg maintenance doses (Cohort 2), and a 27 mg/kg loading dose and 16 mg/kg maintenance doses (Cohort 3). Planned doses may be adjusted in response to the data. Additional participants and/or additional dosing cohorts may be added as needed based on the data.
On Day 1, participants will be randomized to receive either MTX-463 or matched placebo. The randomized participants will receive a single loading dose on Day 1 followed by 2 maintenance doses of study drug on Day 8 and Day 22. Participants will be housed inpatient from Day -1 through post-dose observation on Day 8 and from Day 21 through assessments on Day 29. All other visits will be conducted in the outpatient setting. Each participant will undergo assessments at specified timepoints on Days 1 through 82. End-of-study procedures will be completed on Day 50, or upon ET. An EOF assessment of PK and ADA will be completed on Day 82.
Safety and tolerability of MTX-463 will be reviewed through Day 29 by the study Investigator and SRMO to inform dose escalation decisions for the next dose cohort.
Additional cohorts for the SAD and MAD portions of the study may be added as needed to potentially explore lower doses.
Mediar Therapeutics is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: MTX-463
Other: Placebo
MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.
Matching Placebo-- Normal Saline
Incidence of Treatment-Related Adverse Events in healthy volunteers
Clinical Safety Labs are collected, and Adverse Events are assessed in both inpatient and outpatient clinic visits
Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
MTX-463 PK by dose will be evaluated for Cmax, as feasible
Blood serum samples will be collected at protocol-specified timepoints throughout the study
Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
Serum sample results will be summarized for presence of Anti-Drug Antibodies during the SAD and MAD portions of the study.
Blood serum samples will be collected at protocol-specified timepoints throughout the study to assess for the presence and titer (if applicable) of Anti-Drug Antibodies.
Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
MTX-463 PK by dose will be evaluated for AUC0-t, as feasible.
Blood serum samples will be collected at protocol-specified timepoints throughout the study
Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
MTX-463 PK by dose will be evaluated for AUC0-tau (MAD only), as feasible
Blood serum samples will be collected at protocol-specified timepoints throughout the study
Time frame: Through Day 82 (MAD Cohort)
MTX-463 PK by dose will be evaluated for AUC0-∞, as feasible
Blood serum samples will be collected at protocol-specified timepoints throughout the study
Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
Blood serum samples will be collected to determine the level of WISP1 engagement of MTX-463 in healthy adult participants
These assessments will be summarized as: * Change from Baseline in total WISP1 levels * Change from Baseline in free WISP1 levels
Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
To assess the effect of baseline body mass index (BMI) on total and free WISP1 levels
Baseline levels and change from Baseline of the total and free WISP1 levels will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker PRO-C3 for fibrosis in healthy adult participants
Change from Baseline in fibrosis biomarker PRO-C3 will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker PRO-C6 for fibrosis in healthy adult participants
Change from Baseline in fibrosis biomarker PRO-C6 will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker C7M for fibrosis in healthy adult participants
Change from Baseline in fibrosis biomarker C7M will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IFN-γ for inflammation
Baseline levels and change from Baseline of PD biomarker IFN-γ for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-1β for inflammation
Baseline levels and change from Baseline of PD biomarker IL-1β for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-2 for inflammation
Baseline levels and change from Baseline of PD biomarker IL-2 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-4 for inflammation
Baseline levels and change from Baseline of PD biomarker IL-4 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-6 for inflammation
Baseline levels and change from Baseline of PD biomarker IL-6 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-10 for inflammation
Baseline levels and change from Baseline of PD biomarker IL-10 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-12p70 for inflammation
Baseline levels and change from Baseline of PD biomarker IL-12p70 for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker IL-17A for inflammation
Baseline levels and change from Baseline of PD biomarker IL-17A for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker TNF-α for inflammation
Baseline levels and change from Baseline of PD biomarker TNF-α for inflammation will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IFN-γ for inflammation in healthy adult participants
Change from Baseline in pro-inflammatory biomarker IFN-γ will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-1β for inflammation in healthy adult participants
Change from Baseline in pro-inflammatory biomarker IL-1β will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-2 for inflammation in healthy adult participants
Change from Baseline in pro-inflammatory biomarker IL-2 will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-4 for inflammation in healthy adult participants
Change from Baseline in pro-inflammatory biomarker IL-4 will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-6 for inflammation in healthy adult participants
Change from Baseline in pro-inflammatory biomarker IL-6 will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-10 for inflammation in healthy adult participants
Change from Baseline in pro-inflammatory biomarker IL-10 will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-12p70 for inflammation in healthy adult participants
Change from Baseline in pro-inflammatory biomarker IL-12p70 will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker IL-17A for inflammation in healthy adult participants
Change from Baseline in pro-inflammatory biomarker IL-17A will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of MTX-463 on PD biomarker TNF-α for inflammation in healthy adult participants
Change from Baseline in pro-inflammatory biomarker TNF-α will be evaluated.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker PRO-C3 for fibrosis
Baseline levels and change from Baseline of PD biomarker PRO-C3 for fibrosis will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker PRO-C6 for fibrosis
Baseline levels and change from Baseline of PD biomarker PRO-C6 for fibrosis will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
To assess the effect of baseline BMI on PD biomarker C7M for fibrosis
Baseline levels and change from Baseline of PD biomarker C7M for fibrosis will be compared in those with BMIs ≥30 kg/m2 to those with BMIs \<30 kg/m2.
Time frame: Through Day 36 (MAD Cohort)
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in Nov 2024, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MTX-463
Mediar Therapeutics